Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloid 'degrading factor activity': a non-specific calcium-mediated effect.

D L Scott, P Bracken, P A Bacon

    Clinical Science (London, England : 1979)
    |March 1, 1985
    PubMed
    Summary

    Serum contains a factor that appears to degrade amyloid fibrils. However, this "amyloid degrading factor" activity is likely a non-specific, calcium-mediated effect on protein aggregation, not true proteolytic degradation, and may lack clinical significance.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.

    Arthritis research & therapy·2020
    Same author

    Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis.

    Seminars in arthritis and rheumatism·2019
    Same author

    The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life.

    Seminars in arthritis and rheumatism·2019
    Same author

    Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis.

    RMD open·2016
    Same author

    Improving medication adherence in rheumatoid arthritis (RA): a pilot study.

    Psychology, health & medicine·2015
    Same author

    Treat to target in managing inflammatory arthritis.

    British journal of hospital medicine (London, England : 2005)·2015

    Area of Science:

    • Biochemistry
    • Immunology
    • Pathology

    Background:

    • Serum's ability to clarify amyloid-containing gels was attributed to an 'amyloid degrading factor'.
    • This factor was thought to degrade amyloid fibrils, particularly AA amyloid.

    Purpose of the Study:

    • To investigate the nature of the serum 'amyloid degrading factor'.
    • To determine if this activity is specific to amyloid fibrils and its relationship to serum composition and disease states.

    Main Methods:

    • Agarose plate assay using AA amyloid fibrils, AL amyloid fibrils, and reticulin preparations.
    • Correlation analysis with serum albumin concentration and testing of purified albumin.
    • Assessment of effects of EDTA, calcium, magnesium, and enzyme inhibitors.

    Related Experiment Videos

    Main Results:

    • Serum from healthy donors and rheumatoid arthritis patients exhibited 'degrading activity' against AA amyloid and reticulin, but not AL amyloid.
    • This activity correlated with serum albumin concentration and was mimicked by purified albumin.
    • The effect was calcium-dependent, inhibited by calcium/magnesium, and only partially affected by enzyme inhibitors, suggesting a non-specific aggregation change rather than proteolysis.

    Conclusions:

    • Serum 'degrading factor activity' against AA amyloid and reticulin is a non-specific, calcium-mediated effect.
    • The process likely involves altered protein aggregation rather than proteolytic degradation.
    • The pathophysiological significance of this in vitro phenomenon is questionable.